Form 8-K - Current report:
SEC Accession No. 0001193125-22-098113
Filing Date
2022-04-07
Accepted
2022-04-07 07:00:57
Documents
12
Period of Report
2022-04-01
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d314349d8k.htm   iXBRL 8-K 29817
  Complete submission text file 0001193125-22-098113.txt   149333

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20220401.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20220401_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20220401_pre.xml EX-101.PRE 10802
6 EXTRACTED XBRL INSTANCE DOCUMENT d314349d8k_htm.xml XML 3230
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

EIN.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 22812275
SIC: 2834 Pharmaceutical Preparations